Skip to main content
Journal cover image

Brain magnetic resonance spectroscopy: Role in assessing outcomes in Alzheimer's disease

Publication ,  Journal Article
Doraiswamy, PM; Chen, JG; Charles, HC
Published in: CNS Drugs
January 1, 2000

Contemporary 1H-magnetic resonance spectroscopy (MRS) techniques can estimate the levels of brain metabolites with a high reproducibility and add only 10 minutes to a routine or volumetric magnetic resonance imaging scan. In patients with Alzheimer's disease (AD), 1H-MRS demonstrates decreases in N-acetylaspartate (NAA) and increases in myo-inositol (Ino) levels. Changes in NAA and Ino levels correlate with dementia severity and may predict future cognitive decline. 1H-MRS could be a valuable outcome measure in clinical trials of individuals with AD for monitoring disease progression (using NAA and Ino levels) and evaluating therapeutic response to novel drugs (using NAA, choline and Ino levels). Further studies are warranted to evaluate the relative utility of 1H-MRS compared with other imaging markers, such as cerebral blood flow and volumetric measures of atrophy. Protocols combining magnetic resonance perfusion, volumetry and spectroscopy in AD may prove to be powerful research tools.

Duke Scholars

Published In

CNS Drugs

DOI

ISSN

1172-7047

Publication Date

January 1, 2000

Volume

14

Issue

6

Start / End Page

457 / 472

Related Subject Headings

  • Psychiatry
  • 3214 Pharmacology and pharmaceutical sciences
  • 3209 Neurosciences
  • 3202 Clinical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
  • 1109 Neurosciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Doraiswamy, P. M., Chen, J. G., & Charles, H. C. (2000). Brain magnetic resonance spectroscopy: Role in assessing outcomes in Alzheimer's disease. CNS Drugs, 14(6), 457–472. https://doi.org/10.2165/00023210-200014060-00004
Doraiswamy, P. M., J. G. Chen, and H. C. Charles. “Brain magnetic resonance spectroscopy: Role in assessing outcomes in Alzheimer's disease.” CNS Drugs 14, no. 6 (January 1, 2000): 457–72. https://doi.org/10.2165/00023210-200014060-00004.
Doraiswamy PM, Chen JG, Charles HC. Brain magnetic resonance spectroscopy: Role in assessing outcomes in Alzheimer's disease. CNS Drugs. 2000 Jan 1;14(6):457–72.
Doraiswamy, P. M., et al. “Brain magnetic resonance spectroscopy: Role in assessing outcomes in Alzheimer's disease.” CNS Drugs, vol. 14, no. 6, Jan. 2000, pp. 457–72. Scopus, doi:10.2165/00023210-200014060-00004.
Doraiswamy PM, Chen JG, Charles HC. Brain magnetic resonance spectroscopy: Role in assessing outcomes in Alzheimer's disease. CNS Drugs. 2000 Jan 1;14(6):457–472.
Journal cover image

Published In

CNS Drugs

DOI

ISSN

1172-7047

Publication Date

January 1, 2000

Volume

14

Issue

6

Start / End Page

457 / 472

Related Subject Headings

  • Psychiatry
  • 3214 Pharmacology and pharmaceutical sciences
  • 3209 Neurosciences
  • 3202 Clinical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
  • 1109 Neurosciences
  • 1103 Clinical Sciences